WO2001047927A1 - Compound and method for the treatment of pain - Google Patents

Compound and method for the treatment of pain Download PDF

Info

Publication number
WO2001047927A1
WO2001047927A1 PCT/SE2000/002611 SE0002611W WO0147927A1 WO 2001047927 A1 WO2001047927 A1 WO 2001047927A1 SE 0002611 W SE0002611 W SE 0002611W WO 0147927 A1 WO0147927 A1 WO 0147927A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pain
chloro
mmol
pharmaceutically
Prior art date
Application number
PCT/SE2000/002611
Other languages
English (en)
French (fr)
Inventor
Thomas Michael Bare
Dean Gordon Brown
Megan Murphy
Rebecca Ann Urbanek
Wenhua Xiao
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EEP200200350A priority Critical patent/EE200200350A/xx
Priority to JP2001549397A priority patent/JP2003519149A/ja
Priority to PL00356664A priority patent/PL356664A1/xx
Priority to SI200030678T priority patent/SI1244662T1/xx
Priority to DK00987935T priority patent/DK1244662T3/da
Priority to AT00987935T priority patent/ATE294177T1/de
Priority to KR1020027008043A priority patent/KR20020062369A/ko
Priority to UA2002064620A priority patent/UA73332C2/uk
Priority to NZ519390A priority patent/NZ519390A/en
Priority to HU0300313A priority patent/HUP0300313A3/hu
Priority to US10/168,760 priority patent/US6787547B2/en
Priority to AU24203/01A priority patent/AU779703B2/en
Priority to SK879-2002A priority patent/SK8792002A3/sk
Priority to HK03100925.7A priority patent/HK1048811B/en
Priority to MXPA02006155A priority patent/MXPA02006155A/es
Priority to EP00987935A priority patent/EP1244662B1/en
Priority to DE60019807T priority patent/DE60019807T2/de
Priority to IL15020800A priority patent/IL150208A0/xx
Priority to CA002394888A priority patent/CA2394888A1/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to BR0016654-5A priority patent/BR0016654A/pt
Publication of WO2001047927A1 publication Critical patent/WO2001047927A1/en
Priority to BG106831A priority patent/BG106831A/xx
Priority to IS6427A priority patent/IS6427A/is
Priority to NO20022984A priority patent/NO20022984L/no
Priority to US10/934,753 priority patent/US6943165B2/en
Priority to AU2005201344A priority patent/AU2005201344A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Pa is a sensory expe ⁇ ence distinct from sensations of touch, pressure, heat and cold It is often desc ⁇ bed by sufferers by such terms as b ⁇ ght, dull, aching, pricking, cutting or burning and is generally considered to include both the original sensation and the reaction to that sensation. This range of sensations, as well as the va ⁇ ation in perception of pain by different individuals, renders a precise definition of pain difficult, however, many individuals suffer with severe and continuous pain.
  • Pain that is caused by damage to neural structures is often manifest as a neural supersensitivity or hyperalgesia and is termed “neuropathic” pam. Pain can also be “caused” by the stimulation of nociceptive receptors and transmitted over intact neural pathways, such pain is termed “nociceptive” pam.
  • Analgesics are pharmaceutical agents which relieve pain by raising the pain threshold without a loss of consciousness After administration of an analgesic drug a stimulus of greater intensity or longer duration is required before pam is expe ⁇ enced In an individual suffe ⁇ ng from hyperalgesia an analgesic drug may have an anti-hyperalgesic effect
  • agents such as local anaesthetics block transmission in pe ⁇ pheral nerve fibers thereby blocking awareness of pam.
  • General anaesthetics reduce the awareness of pain by producing a loss of consciousness.
  • Tachykinm antagonists have been reported to induce antinociception in animals, which is believed to be analogous to analgesia m man (Maggi et al, J. Auton. Pharmacol. (1993) 13, 23-93).
  • non-peptide NK-1 receptor antagonists have been shown to produce such analgesia.
  • the NK-1 receptor antagonist RP 67,580 produced analgesia with potency comparable to that of morphine (Garret et al, Proc. Natl. Acad. Sci USA (1993) 88, 10208-10212)
  • the opioid analgesics are a well-established class of analgesic agents with morphinelike actions.
  • Synthetic and semi-synthetic opioid analgesics are de ⁇ vatives of five chemical classes of compound: phenanthrenes; phenylheptylammes; phenylpipe ⁇ dines; morphinans. and benzomorphans.
  • Pharmacologically these compounds have diverse activities, thus some are strong agonists at the opioid receptors (e.g. morphine); others are moderate to mild agonists (e.g. codeine); still others exhibit mixed agonist-antagonist activity (e.g. nalbuphine); and yet others are partial agonists (e.g. nalorphine).
  • an opioid partial agonist such as nalorphine, (the N-alkyl analogue of morphine) will antagonize the analgesic effects of morphine, when given alone it can be a potent analgesic in its own right.
  • opioid analgesics Of all of the opioid analgesics, morphine remains the most widely used, but, in addition to its therapeutic properties, it has a number of drawbacks including respiratory depression, decreased gastrointestinal motility (resulting in constipation), nausea and vomiting. Tolerance and physical dependence also limit the clinical uses of opioid compounds.
  • Aspirin and other salicylate compounds are frequently used in treatment to interrupt amplification of the inflammatory process in rheumatoid diseases and arthritis and temporarily relieve the pain.
  • Other drug compounds used for these purposes include phenylpropionic acid derivatives such as Ibuprofen and Naproxen, Sulindac, phenyl butazone, corticosteroids.
  • antimalarials such as chloroquine and hydroxychloroquine sulfate, and fenemates (J. Hosp. Pharm., 36:622 (May 1979)). These compounds, however, are ineffective for neuropathic pain.
  • NMDA receptors are defined by the binding of N-methyl-D-aspartate (NMDA) comprise a receptor/ion channel complex with several different identified binding domains.
  • NMDA itself is a molecule structurally similar to glutamate (Glu) which binds at the glutamate binding suite and is highly selective and potent in activating the NMDA receptor (Watkins (1987); Olney (1989)). Many compounds are known that bind at the NMDA/Glu binding site (for example
  • non-competitive NMDA antagonists bind at other sites in the NMDA receptor complex (examples are phencyclidine, dizocilpine, ketamine, tiletamine, CNS 1102, dextromethorphan, memantine, kynurenic acid, CNQX, DNQX, 6,7-DCQX, 6,7- DCHQC, R(+)-HA-966, 7-chloro-kynurenic acid, 5,7-DCKA, 5-iodo-7-chloro-kynurenic acid, MDL-28,469, MDL-100,748, MDL-29,951, L-689,560, L-687,414, ACPC, ACPCM, ACPCE, arcaine, diethylenetriamine, 1,10-diaminodecane, 1,12-diaminododecane, ifenprodil, and SL- 82.0715). These compounds have been extensively reviewed by Roga
  • glutamate In addition to its physiological function, glutamate (Glu) can be neurotoxic. Glu neurotoxicity is referred to as "excitotoxicity" because the neurotoxic action of Glu, like its beneficial actions, is mediated by an excitatory process (Olney (1990); Choi (1992)).
  • Glu when Glu is released at a synaptic receptor, it binds only transiently and is then rapidly removed from the receptor by a process that transports it back into the cell. Under certain abnormal conditions, including stroke, epilepsy and CNS trauma, Glu uptake fails and Glu accumulates at the receptor resulting in a persistent excitation of electrochemical activity that leads to the death of neurons that have Glu receptors. Many neurons in the CNS have Glu receptors, so excitotoxicity can cause an enormous amount of CNS damage.
  • Acute excitotoxicity injury can occur as a result of ischemic events, hypoxic events, trauma to the brain or spinal cord, certain types of food poisoning which involve an excitotoxic poison such as domoic acid, and seizure-mediated neuronal degeneration, which can result from persistent epileptic seizure activity (status epilepticus).
  • NMDA receptor one receptor subtype through which Glu mediates a substantial amount of CNS injury, and it is well established that NMDA antagonists are effective in protecting CNS neurons against excitotoxic degeneration in these acute CNS injury syndromes (Choi (1988); Olney (1990)).
  • NMDA antagonists may prove useful in the therapeutic management of such chronic diseases.
  • PCP also known as "angel dust”
  • PCP acts at a "PCP recognition site" within the ion channel of the NMDA Glu receptor.
  • PCP acts as a non- competitive antagonist that blocks the flow of ions through the NMDA ion channel.
  • drugs which act at the PCP site as non-competitive NMDA antagonists are likely to have psychotomimetic side effects.
  • certain competitive and non-competitive NMDA antagonists can cause similar pathomorphological effects in rat brain (Olney et. al., (1991); Hargreaves et. al., (1993)).
  • Such compounds also have psychotomimetic effects in humans (Kristensen et. al., (1992); Herrling (1994); Grotta (1994)).
  • NMDA receptor complex The glycine binding site of the NMDA receptor complex is distinguishable from the Glu and PCP binding sites. Also, it has recently been discovered that NMDA receptors occur as several subtypes which are characterized by differential properties of the glycine binding site of the receptor. Many compounds that bind at the NMDA receptor glycine site, useful for the treatment of stroke and neurodegenerative conditions, have been described in U.S. Patents 5,604,227; 5,733,910; 5,599,814; 5,593,133; 5,744,471; 5,837,705 and 6,103,721. Summary of the Invention
  • the invention provides a compound, 7-chloro-4-hydroxy-2- (2-chloro-4-methylphenyl)- 1 ,2,5 , 10-tetrahy dropyridazino [4,5 -b] quinoline- 1 , 10-dione , according to structural diagram I;
  • the invention provides a method for the treatment of pain using a compound in accord with structural diagram I, the method comprising administering a pain- ameliorating effective amount of the compound.
  • the method comprises administration of a pain-ameliorating effective amount of the compound according to structural diagram I in the form of a pharmaceutical composition comprising a compound according to structural diagram I as an active ingredient together with one or more pharmaceutically-acceptable additives.
  • the method comprises binding the compound of the invention to the NMDA receptor glycine site of a warm-blooded animal, such as a human being, so as to beneficially inhibit the activity of the NMDA receptor.
  • Another aspect of the invention is a method for making the compound in accord with structural diagram I.
  • compositions which contain the compound in accord with structural diagram I and the use of the compound in accord with structural diagram I for the preparation of medicaments and pharmaceutical compositions.
  • the invention provides a compound, 7-chloro-4-hydroxy-2-(2-chloro-4- methylphenyl)- 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline- 1 , 10-dione, pharmaceutically- acceptable salts thereof, methods of making the compound and its salts, pharmaceutical compositions containing the compound or salts thereof and methods for using the compound, the salts and the pharmaceutical compositions.
  • Suitable pharmaceutically-acceptable salts of compounds of the invention include acid addition salts such as methanesulphonate, fumarate, hydrochloride, hydrobromide, citrate, tris(hydroxymethyl)aminomethane, maleate and salts formed with phosphoric and sulphuric acid.
  • suitable salts are base salts such as an alkali metal salts for example sodium, alkaline earth metal salts for example calcium or magnesium, organic amine salts for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, choline, NN-dibenzylethylamine or amino acids such as lysine.
  • the compound of the invention or a pharmaceutically-acceptable salt thereof for the therapeutic treatment which may include prophylactic treatment, of pain in mammals, which may be humans
  • the compound can be formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • Suitable pharmaceutical compositions that contain a compound of the invention may be administered in conventional ways, for example by oral, topical, parenteral, buccal, nasal, vaginal or rectal administration or by inhalation.
  • a compound of the invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.
  • a preferred route of administration is orally by tablet or capsule.
  • a pharmaceutical composition of this invention may also contain one or more other pharmacologically-active agents, or such pharmaceutical composition may be simultaneously or sequentially co-administered with one or more other pharmacologically-active agents.
  • compositions of this invention will normally be administered so that a pain-ameliorating effective daily dose is received by the subject.
  • the daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease condition being treated according to principles known in the art.
  • a preferred dosage regime is once daily.
  • a further embodiment of the invention provides a pharmaceutical composition which contains a compound of the invention as defined herein or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable additive such as an excipient or carrier.
  • a yet further embodiment of the invention provide the use of the compound of the invention, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament useful for binding to the NMDA receptor glycine site in a warm-blooded animal such as a human being.
  • Still another embodiment of the invention provides a method of binding the compound of the invention to the NMDA receptor glycine site of a warm-blooded animal, such as a human being, in need of treatment for pain, which method comprises administering to said animal an effective amount of a compound of structural diagram I or a pharmaceutically- acceptable salt thereof.
  • concentrations were carried out by rotary evaporation in vacuo; operations were carried out at ambient temperature, that is in the range 18-26 °C and under a nitrogen atmosphere; column chromatography (by the flash procedure) was performed on Merck Kieselgel silica (Art.
  • CMC is l-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho- -toluenesulfonate
  • DCM is dichloromethane
  • DCU is dicyclohexyl urea
  • DHC is 1,3-dicyclohexylcarbodiimide
  • DMAP is 4-(dimethylamino)pyridine
  • DMF is N,N-dimethylformamide
  • DMSO dimethylsulphoxide
  • m/s mass spectroscopy
  • NMP N-methylpyrrolidinone
  • NMR nuclear magnetic resonance
  • p.o. is per os
  • THF is tetrahydrofuran, and t.i.d. is three times daily.
  • the examples and tests described herein are intended to illustrate but not limit the invention. Examples; Example 1:
  • the compound of the invention 7-chloro-4-hydroxy-2-(2-chloro-4-methylphenyl)- 1,2,5, 10-tetrahydropyridazino[4,5-b]quinoline- 1,10-dione, may be prepared by the following procedure:
  • Dimethyl 7-chloro-4-hydroxyquinoline-2,3-dicarboxylate A stirred mixture of methyl 2-amino-4-chlorobenzoate (2.50 g, 13.5 mmol) and dimethyl acetylenedicarboxylate (2.05 g, 14.4 mmol) in tert-butanol (22 ml) was refluxed for 7 hours under a nitrogen atmosphere. After adding additional dimethyl acetylenedicarboxylate (1.16 g, 8.13 mmol) and refluxing another 2.5 hours, the reaction mixture was allowed to cool to room temperature and potassium tert-butoxide (1.56 g, 13.9 mmol) was added in one portion.
  • 3-Carbomethoxy-2-pyrrolidinocarbamide-7-chloro-4-hvdroxyquinoline To a suspension of 3-carbomethoxy-7-chloro-4-hydroxyquinoline-2-carboxylic acid (2.25 g, 8.0 mmol) in THF (20 mL) at ambient temperature under a N 2 atmosphere was added dicyclohexylcarbodiimide (1.65 g, 8.0 mmol) and pyrrolidine (0.596 g, 8.4 mmol). The reaction was stirred room temperature for 15 hours after which time the by-product urea was removed via filtration.
  • the material was dissolved in methylene chloride (400 mL), washed with distilled water (2 x 150 mL), and extracted with 10% NaHCO 3 (2 x 500 mL). The organic layer was dried over Na 2 SO 4 , concentrated and dried in vacuo to afford a light tan foam.
  • the material was purified by flash chromatography on silica gel using a gradient of 95:5 to 85:15 chloroform:methanol as eluant to afford 15.42 g (61%) of the desired product as a white solid.
  • the solution was filtered through a 0.2 micron nylon syringe filter.
  • the solution was reduced by rotary evaporation to 1.01 g (>100%) yellow solid.
  • the solid was re- crystallized from refluxing ethanol (25 mL), and the solution was allowed to crystallize slowly and without agitation. After about 2 h, the crystals were collected by vacuum filtration.
  • Rat Brain Membranes The rat brain membranes used in the experiments were obtained from Analytical Biological Services Inc., and were prepared substantially in accordance with the method of B.M. Baron et al, J. Pharmacol. Exp. Ther. 250, 162 (1989). Briefly, fresh brain tissue including cerebral cortex and hippocampus from male Sprague Dawley rats was homogenized in 0.32 M sucrose and centrifuged at low speed to separate cellular membranes from other cellular components. The membranes were then washed 3 times using deionized water, followed by treatment with 0.04% Triton X-100. Finally, membranes were washed six times in 50 mM Tris citrate buffer, pH 7.4, and frozen at -80 °C until use.
  • [ 3 H]MDL105,519 (72 Ci/mmol) was purchased from Amersham. Cold MDL105,519 was purchased from Sigma/RBI. Binding assays were performed substantially in accordance with the protocol of B.M. Baron et al, J. Pharmacol. Exp. Ther. 279, 62 (1996), as follows. On the day of the experiment, brain membranes were thawed at room temperature and suspended in 50 mM tris acetate buffer, pH 7.4 ("TAB"). Seventy-five micro grams per milliliter protein (by using the BioRad dye) were used for competition binding. The experiments were carried out using 96-well plates.
  • Membranes were incubated with 20 ⁇ L of compounds of various concentrations and 1.2 nM [ 3 H]MDL 105,519 for 30 minutes at room temperature in a total volume of 250 ⁇ L.
  • Non specific binding was determined by using 100 ⁇ M of unlabeled MDL105,519.
  • the unlabeled MDL105,519 and compounds were dissolved as 12.5 mM stock solutions in DMSO. Final DMSO concentration in each well was kept below 1%, which concentration was found not to alter the binding results.
  • unbound [ 3 H]MDL105,519 was removed by filtration onto GF/B Unifilter plates using a Packard harvester. Filters were washed four times with ice cold TAB (total of 1.2 mL buffer).
  • Human Brain Membranes Human brain membranes were obtained from Analytical Biological Services Inc., and assays were performed as described for rat membranes Test B: Formalin test:
  • the Formalin test assesses the inhibitory effects of orally administered compounds on formalin-induced nociceptive behaviors in rats (D. Dubuisson, et al, Pain 4, 161-174 (1977); H. Wheeler-Aceto et al, Psychopharmacology 104, 35-44 (1991); TJ. Coderre, et al, Pain 54, 43-50 (1993)).
  • a first phase response caused by acute nociception to the noxious chemical (formalin) injected into the paw, occurs between 0 to 5 minutes.
  • a quiescent period of between 5 to 15 min post injection follows.
  • a second phase response caused by sensitization of the central neurons in the dorsal horn, occurs after 15 minutes and lasts up to 60 minutes. Central sensitization augments a noxious afferent input causing a stronger pain barrage to be transmitted to the brain. Inhibition of the second phase response indicates a spinal mechanism of drug action.
  • the procedure for the formalin test is as follows: male rats are placed in a plexiglass chamber and observed for 30-45 min. to observe their baseline activity. Multiple groups of animals are pretreated with either vehicle or different doses of a test compound. Animals are dosed 3 hours prior to injection of formalin into a hind paw (under the dorsal skin) with 0.05 mL of sterile 1% formalin.
  • the number of paw flinches (responses) during first phase (0-5 min.) and second phase (20-35 min.) are scored and recorded.
  • Flinch response is calculated as percentage of inhibition compared with the mean score of a saline control group.
  • the ED 50 is the dose of compound which produces 50% inhibition of nociceptive response.
  • % inhibition of nociceptive response 100 x (number of responses in vehicle group - number of responses in compound group) (number of responses in vehicle group) Student's t-test was used for statistical analysis to determine the significance of compound effects. Compounds are considered active based on their ability to inhibit flinch responses.
  • Test C Neuropathic pain model (Chronic Constnction IniurvV The Chronic Constnction Injury (“CCI”) test models neuropathic pain associated with nerve injuries that can arise directly from trauma and compression, or indirectly from a wide range of diseases such as infection, cancer, metabolic conditions, toxins, nut ⁇ tional deficiencies, immunological dysfunction, and musculoskeletal changes. In the model a unilateral pe ⁇ pheral hyperalgesia is produced in rats by nerve ligation (G.J Bennett, et al, Pain 33, 87-107 (1988)).
  • CCI Chronic Constnction Injury
  • Sprague-Dawley rats 250-350 g are anesthetized with sodium pentobarbital and the common sciatic nerve is exposed at the level of the mid thigh by blunt dissection through the biceps femo ⁇ s
  • a section of nerve (about 7 mm), proximal to the sciatic t ⁇ fucation, is freed of tissue and hgated at four positions with chromic gut suture
  • the suture is tied with about 1 mm spacing between ligatures. The incision is closed m layers and the animals are allowed to recuperate Thermal hyperalgesia is measured using a paw- withdrawal test (K. Hargreaves, et al, Pain 32, 77-88 (1988)).
  • Injured paws with hgated nerves show shorter paw withdrawal latencies compared to the uninjured or sham operated paws.
  • Response to test compounds are evaluated at different times after oral administration to determine onset and duration of compound effect.
  • Dose response studies are conducted with multiple groups of CCI rats dosed orally with either vehicle or the test compound three times daily with either vehicle or the test compound for 5 days. Paw withdrawal latencies are measured each day 10 mm before and 2 or 3 hr after the first daily dose. Efficacy is calculated as mean percentage decrease of hyperalgesia over 5 dosing days compared to vehicle-treated group.
  • MED minimum effective dose
  • Table 1 shows the results from Tests A, B and C for the compound of the invention.
  • the effective dose the compound of the invention that caused a 50% decrease in sensitivity to a painful stimulus was about 100 mg/Kg which dose was comparable to the dose of gabapentin required to achieve a similar result.
  • the minimal effective dose of the compound of the invention was less than 2 mg/Kg/day to achieve 65% anti-hyperalgesia.
  • about 90 mg/Kg/day of gabapentin is required to achieve about 46% anti-hyperalgesia.
  • the compound of the invention When administered by intrathecal injection, the compound of the invention inhibited the development of NMDA induced behavior/seizure with an ED 50 of 110 nmol.
  • the compound of the invention was also tested for binding to a panel of more than 80 non-NMDA receptors.
  • the compound showed no significant interaction with any tested receptor other than the NMDA receptor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/SE2000/002611 1999-12-23 2000-12-19 Compound and method for the treatment of pain WO2001047927A1 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SK879-2002A SK8792002A3 (en) 1999-12-23 2000-12-19 Quinoline-based compound, pharmaceutical composition containing same and use thereof
PL00356664A PL356664A1 (en) 1999-12-23 2000-12-19 Compound and method for the treatment of pain
SI200030678T SI1244662T1 (cs) 1999-12-23 2000-12-19
DK00987935T DK1244662T3 (da) 1999-12-23 2000-12-19 Pyridazinoquinolinderivater og fremgangsmåde til behandling af smerter
AT00987935T ATE294177T1 (de) 1999-12-23 2000-12-19 Pyridazino-quinolin derivat und verfahren zur behandlung von schmerz
KR1020027008043A KR20020062369A (ko) 1999-12-23 2000-12-19 통증의 치료를 위한 화합물 및 방법
UA2002064620A UA73332C2 (en) 2000-09-29 2000-12-19 A compound, a method for treating pain (variants) and a pharmaceutical composition (variants)
NZ519390A NZ519390A (en) 1999-12-23 2000-12-19 7-Chloro-4-hydroxy-2-(2-chloro-4-methylphenyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione useful for treating pain
HU0300313A HUP0300313A3 (en) 1999-12-23 2000-12-19 Compound, pharmaceutical composition containing it and its use for the treatment of pain
US10/168,760 US6787547B2 (en) 1999-12-23 2000-12-19 Compound and method for the treatment of pain
MXPA02006155A MXPA02006155A (es) 1999-12-23 2000-12-19 Compuesto y metodo para el tratamiento del dolor.
EEP200200350A EE200200350A (et) 1999-12-23 2000-12-19 Ühend ja meetod valu raviks
HK03100925.7A HK1048811B (en) 1999-12-23 2000-12-19 Pyridazino quinoline derivative and method for the treatment of pain
AU24203/01A AU779703B2 (en) 1999-12-23 2000-12-19 Compound and method for the treatment of pain
EP00987935A EP1244662B1 (en) 1999-12-23 2000-12-19 Pyridazino quinoline derivative and method for the treatment of pain
DE60019807T DE60019807T2 (de) 1999-12-23 2000-12-19 Pyridazino-quinolin derivat und verfahren zur behandlung von schmerz
IL15020800A IL150208A0 (en) 1999-12-23 2000-12-19 Compound and method for the treatment of pain
CA002394888A CA2394888A1 (en) 1999-12-23 2000-12-19 Compound and method for the treatment of pain
JP2001549397A JP2003519149A (ja) 1999-12-23 2000-12-19 痛みの処置のための化合物および方法
BR0016654-5A BR0016654A (pt) 1999-12-23 2000-12-19 Composto, método para o tratamento da dor, e, composição farmacêutica
BG106831A BG106831A (en) 1999-12-23 2002-06-18 Compound and method for the treatment of pain
IS6427A IS6427A (is) 1999-12-23 2002-06-19 Efnasamband og aðferð til að meðhöndla sársauka
NO20022984A NO20022984L (no) 1999-12-23 2002-06-20 Forbindelse og fremgangsmåte for behandling av smerte
US10/934,753 US6943165B2 (en) 1999-12-23 2004-09-03 Compound and method for the treatment of pain
AU2005201344A AU2005201344A1 (en) 1999-12-23 2005-03-29 Compound and method for the treatment of pain

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17190699P 1999-12-23 1999-12-23
US60/171,906 1999-12-23
US23678300P 2000-09-29 2000-09-29
US60/236,783 2000-09-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10168760 A-371-Of-International 2000-12-19
US10/934,753 Continuation US6943165B2 (en) 1999-12-23 2004-09-03 Compound and method for the treatment of pain

Publications (1)

Publication Number Publication Date
WO2001047927A1 true WO2001047927A1 (en) 2001-07-05

Family

ID=26867555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2000/002611 WO2001047927A1 (en) 1999-12-23 2000-12-19 Compound and method for the treatment of pain

Country Status (29)

Country Link
EP (1) EP1244662B1 (cs)
JP (1) JP2003519149A (cs)
KR (1) KR20020062369A (cs)
CN (1) CN1188413C (cs)
AR (1) AR027037A1 (cs)
AT (1) ATE294177T1 (cs)
AU (1) AU779703B2 (cs)
BG (1) BG106831A (cs)
BR (1) BR0016654A (cs)
CA (1) CA2394888A1 (cs)
CO (1) CO5271689A1 (cs)
CZ (1) CZ296877B6 (cs)
DE (1) DE60019807T2 (cs)
DK (1) DK1244662T3 (cs)
EE (1) EE200200350A (cs)
ES (1) ES2239632T3 (cs)
HK (1) HK1048811B (cs)
HU (1) HUP0300313A3 (cs)
IL (1) IL150208A0 (cs)
IS (1) IS6427A (cs)
MX (1) MXPA02006155A (cs)
MY (1) MY133596A (cs)
NO (1) NO20022984L (cs)
NZ (1) NZ519390A (cs)
PL (1) PL356664A1 (cs)
PT (1) PT1244662E (cs)
RU (1) RU2234507C2 (cs)
SK (1) SK8792002A3 (cs)
WO (1) WO2001047927A1 (cs)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006068617A1 (en) * 2004-12-23 2006-06-29 Astrazeneca Ab A new manufacturing process for the preparation of halogen substituted 4-hydroxy-2-(2-chloro-4-methylphenyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2074992B1 (en) * 2005-04-08 2015-05-20 Abbott Laboratories Oral pharmaceutical formulations comprising salts of fenofibric acid
JP5790533B2 (ja) * 2012-02-14 2015-10-07 住友化学株式会社 フェニルヒドラジン−β−カルボキシレート化合物の精製方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011244A1 (en) * 1993-10-22 1995-04-27 Zeneca Limited Pyridazino quinoline compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011244A1 (en) * 1993-10-22 1995-04-27 Zeneca Limited Pyridazino quinoline compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006068617A1 (en) * 2004-12-23 2006-06-29 Astrazeneca Ab A new manufacturing process for the preparation of halogen substituted 4-hydroxy-2-(2-chloro-4-methylphenyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione

Also Published As

Publication number Publication date
MY133596A (en) 2007-11-30
RU2234507C2 (ru) 2004-08-20
KR20020062369A (ko) 2002-07-25
CA2394888A1 (en) 2001-07-05
CZ20022177A3 (cs) 2002-11-13
AU2420301A (en) 2001-07-09
CN1188413C (zh) 2005-02-09
NZ519390A (en) 2003-07-25
NO20022984D0 (no) 2002-06-20
EP1244662B1 (en) 2005-04-27
HUP0300313A2 (hu) 2003-06-28
IL150208A0 (en) 2002-12-01
EP1244662A1 (en) 2002-10-02
NO20022984L (no) 2002-08-20
IS6427A (is) 2002-06-19
CZ296877B6 (cs) 2006-07-12
CN1411459A (zh) 2003-04-16
HK1048811A1 (en) 2003-04-17
DE60019807D1 (de) 2005-06-02
JP2003519149A (ja) 2003-06-17
AU779703B2 (en) 2005-02-10
DK1244662T3 (da) 2005-07-11
BG106831A (en) 2003-03-31
MXPA02006155A (es) 2002-12-05
AR027037A1 (es) 2003-03-12
HUP0300313A3 (en) 2007-05-02
DE60019807T2 (de) 2006-01-19
PT1244662E (pt) 2005-07-29
ES2239632T3 (es) 2005-10-01
EE200200350A (et) 2003-10-15
BR0016654A (pt) 2002-09-03
ATE294177T1 (de) 2005-05-15
SK8792002A3 (en) 2003-05-02
PL356664A1 (en) 2004-06-28
CO5271689A1 (es) 2003-04-30
HK1048811B (en) 2005-09-30

Similar Documents

Publication Publication Date Title
EP1244663B1 (en) Compounds and methods for the treatment of pain
EP1244662B1 (en) Pyridazino quinoline derivative and method for the treatment of pain
US6787547B2 (en) Compound and method for the treatment of pain
US6933297B2 (en) 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain
EP1244664A1 (en) Compounds and methods for the treatment of pain
US6943165B2 (en) Compound and method for the treatment of pain
ZA200204781B (en) Compound and method for the treatment of pain.
US6730675B2 (en) Compounds and methods for the treatment of pain
US6833368B2 (en) 1, 2, 5, 10-tetrahydropyridazino[4, 5-b]quinoline-1,10-diones and their use for the treatment of pain
US20040053929A1 (en) 1, 2, 5, 10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain
EP1577311A1 (en) Salts of a pyridazino aquinoline derivative and use for the treatment of pain
AU2005201344A1 (en) Compound and method for the treatment of pain
HK1080844A (en) Salts of a pyridazino aquinoline derivative and use for the treatment of pain
US20050227977A1 (en) Substituted 1,2,5,10-tetrahydropyridazino [4,5-b]quinoline-1,10-dione compounds and methods for the treatment of pain
EP1325005A1 (en) 1,2,5,10-tetrahydropyridazino 4,5-b]quinoline-1,10-diones and their use for the treatment of pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 24203/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00725/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 519390

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 150208

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002/04781

Country of ref document: ZA

Ref document number: 200204781

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2000 106831

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2394888

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 008174318

Country of ref document: CN

Ref document number: 8792002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/006155

Country of ref document: MX

Ref document number: PV2002-2177

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2001 549397

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027008043

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000987935

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2002 2002115270

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027008043

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000987935

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-2177

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10168760

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 519390

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 519390

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2000987935

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 24203/01

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: PV2002-2177

Country of ref document: CZ